Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Staudt Website

Louis M. Staudt, M.D., Ph.D.

Selected Publications

1)  Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO, Staudt LM.
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling.
Nature. 403: 503-11, 2000.
[Journal]
2)  Ngo VN, Davis RE, Lamy L, Yu X, Zhao H, Lenz G, Lam LT, Dave S, Yang L, Powell J, Staudt LM.
A loss-of-function RNA interference screen for molecular targets in cancer.
Nature. 441: 106-10, 2006.
[Journal]
3)  Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, Kohlhammer H, Lamy L, Zhao H, Yang Y, Xu W, Shaffer AL, Wright G, Xiao W, Powell J, Jiang JK, Thomas CJ, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Connors JM, Johnson NA, Rimsza LM, Campo E, Jaffe ES, Wilson WH, Delabie J, Smeland EB, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Pierce SK, Staudt LM.
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.
Nature. 463: 88-92, 2010.
[Journal]
4)  Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim KH, Kohlhammer H, Xu W, Yang Y, Zhao H, Shaffer AL, Romesser P, Wright G, Powell J, Rosenwald A, Muller-Hermelink HK, Ott G, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Staudt LM.
Oncogenically active MYD88 mutations in human lymphoma.
Nature. 470: 115-9, 2011.
[Journal]
5)  Schmitz R, Young RM, Ceribelli M, Jhavar S, Xiao W, Zhang M, Wright G, Shaffer AL, Hodson DJ, Buras E, Liu X, Powell J, Yang Y, Xu W, Zhao H, Kohlhammer H, Rosenwald A, Kluin P, Müller-Hermelink HK, Ott G, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Ogwang MD, Reynolds SJ, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Pittaluga S, Wilson W, Waldmann TA, Rowe M, Mbulaiteye SM, Rickinson AB, Staudt LM.
Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics.
Nature. 490: 116-20, 2012.
[Journal]
6)  Ippolito GC, Dekker JD, Wang YH, Lee BK, Shaffer AL, Lin J, Wall JK, Lee BS, Staudt LM, Liu YJ, Iyer VR, Tucker HO.
Dendritic cell fate is determined by BCL11A.
Proc. Natl. Acad. Sci. U.S.A. 111: E998-1006, 2014.
[Journal]
7)  Scott DW, Wright GW, Williams PM, Lih C, Walsh W, Jaffe ES, Rosenwald A, Campo E, Chan WC, Connors JM, Smeland EB, Mottok A, Braziel RM, Ott G, Delabie J, Tubbs RR, Cook JR, Weisenburger DD, Greiner TC, Glinsmann-Gibson BJ, Fu K, Staudt LM, Gascoyne RD, Rimsza LM.
Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin embedded tissue.
Blood. 123: 1214-7, 2014.
[Journal]
8)  Roschewski M, Staudt LM, Wilson WH.
Diffuse large B-cell lymphoma-treatment approaches in the molecular era.
Nat Rev Clin Oncol. 11: 12-23, 2014.
[Journal]
9)  Yang Y, Schmitz R, Mitala JJ, Whiting A, Xiao W, Ceribelli M, Wright GW, Zhao H, Yang Y, Xu W, Rosenwald A, Ott G, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Wiestner A, Kruhlak MJ, Iwai K, Bernal F, Staudt LM.
Essential Role of the Linear Ubiquitin Chain Assembly Complex in Lymphoma Revealed by Rare Germline Polymorphisms.
Cancer Discov. 4: 480-93, 2014.
[Journal]
10)  Iqbal J, Wright G, Wang C, Rosenwald A, Gascoyne RD, Weisenburger DD, Greiner TC, Smith L, Guo S, Wilcox RA, Teh BT, Lim ST, Tan SY, Rimsza LM, Jaffe ES, Campo E, Martinez A, Delabie J, Braziel RM, Cook JR, Tubbs RR, Ott G, Geissinger E, Gaulard P, Piccaluga PP, Pileri SA, Au WY, Nakamura S, Seto M, Berger F, de Leval L, Connors JM, Armitage J, Vose J, Chan WC, Staudt LM.
Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma.
Blood. 123: 2915-23, 2014.
[Journal]
11)  Bouska A, McKeithan TW, Deffenbacher KE, Lachel C, Wright GW, Iqbal J, Smith LM, Zhang W, Kucuk C, Rinaldi A, Bertoni F, Fitzgibbon J, Fu K, Weisenburger DD, Greiner TC, Dave BJ, Gascoyne RD, Rosenwald A, Ott G, Campo E, Rimsza LM, Delabie J, Jaffe ES, Braziel RM, Connors JM, Staudt LM, Chan WC.
Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma.
Blood. 123: 1681-90, 2014.
[Journal]
12)  Mathews Griner LA, Guha R, Shinn P, Young RM, Keller JM, Liu D, Goldlust IS, Yasgar A, McKnight C, Boxer MB, Duveau DY, Jiang J, Michael S, Mierzwa T, Huang W, Walsh MJ, Mott BT, Patel P, Leister W, Maloney DJ, Leclair CA, Rai G, Jadhav A, Peyser BD, Austin CP, Martin SE, Simeonov A, Ferrer M, Staudt LM, Thomas CJ.
High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells.
Proc. Natl. Acad. Sci. U.S.A. 111: 2349-54, 2014.
[Journal]
13)  Schmitz R, Ceribelli M, Pittaluga S, Wright G, Staudt LM.
Oncogenic mechanisms in Burkitt lymphoma.
Cold Spring Harb Perspect Med. 4, 2014.
[Journal]
14)  Lamy L, Ngo VN, Emre NC, Shaffer AL, Yang Y, Tian E, Nair V, Kruhlak MJ, Zingone A, Landgren O, Staudt LM.
Control of autophagic cell death by caspase-10 in multiple myeloma.
Cancer Cell. 23: 435-49, 2013.
[Journal]
15)  O'Shea JJ, Holland SM, Staudt LM.
JAKs and STATs in immunity, immunodeficiency, and cancer.
N. Engl. J. Med. 368: 161-70, 2013.
[Journal]
16)  Chiorazzi M, Rui L, Yang Y, Ceribelli M, Tishbi N, Maurer CW, Ranuncolo SM, Zhao H, Xu W, Chan WC, Jaffe ES, Gascoyne RD, Campo E, Rosenwald A, Ott G, Delabie J, Rimsza LM, Shaham S, Staudt LM.
Related F-box proteins control cell death in Caenorhabditis elegans and human lymphoma.
Proc. Natl. Acad. Sci. U.S.A. 110: 3943-8, 2013.
[Journal]
17)  Young RM, Staudt LM.
Targeting pathological B cell receptor signalling in lymphoid malignancies.
Nat Rev Drug Discov. 12: 229-43, 2013.
[Journal]
18)  Snow AL, Xiao W, Stinson JR, Lu W, Chaigne-Delalande B, Zheng L, Pittaluga S, Matthews HF, Schmitz R, Jhavar S, Kuchen S, Kardava L, Wang W, Lamborn IT, Jing H, Raffeld M, Moir S, Fleisher TA, Staudt LM, Su HC, Lenardo MJ.
Congenital B cell lymphocytosis explained by novel germline CARD11 mutations.
J. Exp. Med. 209: 2247-61, 2012.
[Journal]
19)  Yang Y, Shaffer AL, Emre NC, Ceribelli M, Zhang M, Wright G, Xiao W, Powell J, Platig J, Kohlhammer H, Young RM, Zhao H, Yang Y, Xu W, Buggy JJ, Balasubramanian S, Mathews LA, Shinn P, Guha R, Ferrer M, Thomas C, Waldmann TA, Staudt LM.
Exploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma.
Cancer Cell. 21: 723-37, 2012.
[Journal]
20)  Chen E, Staudt LM, Green AR.
Janus kinase deregulation in leukemia and lymphoma.
Immunity. 36: 529-41, 2012.
[Journal]
21)  Shaffer AL, Young RM, Staudt LM.
Pathogenesis of human B cell lymphomas.
Annu. Rev. Immunol. 30: 565-610, 2012.
[Journal]
22)  Annunziata CM, Hernandez L, Davis RE, Zingone A, Lamy L, Lam LT, Hurt EM, Shaffer AL, Kuehl WM, Staudt LM.
A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression.
Blood. 117: 2396-404, 2011.
[Journal]
23)  Steidl C, Shah SP, Woolcock BW, Rui L, Kawahara M, Farinha P, Johnson NA, Zhao Y, Telenius A, Neriah SB, McPherson A, Meissner B, Okoye UC, Diepstra A, van den Berg A, Sun M, Leung G, Jones SJ, Connors JM, Huntsman DG, Savage KJ, Rimsza LM, Horsman DE, Staudt LM, Steidl U, Marra MA, Gascoyne RD.
MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers.
Nature. 471: 377-81, 2011.
[Journal]
24)  Lenz G, Staudt LM.
Aggressive lymphomas.
N. Engl. J. Med. 362: 1417-29, 2010.
[Journal]
25)  Rui L, Emre NC, Kruhlak MJ, Chung HJ, Steidl C, Slack G, Wright GW, Lenz G, Ngo VN, Shaffer AL, Xu W, Zhao H, Yang Y, Lamy L, Davis RE, Xiao W, Powell J, Maloney D, Thomas CJ, Möller P, Rosenwald A, Ott G, Muller-Hermelink HK, Savage K, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Weisenburger DD, Chan WC, Gascoyne RD, Levens D, Staudt LM.
Cooperative epigenetic modulation by cancer amplicon genes.
Cancer Cell. 18: 590-605, 2010.
[Journal]
26)  Staudt LM.
Oncogenic activation of NF-kappaB.
Cold Spring Harb Perspect Biol. 2: a000109, 2010.
[Journal]
27)  Choi WW, Weisenburger DD, Greiner TC, Piris MA, Banham AH, Delabie J, Braziel RM, Geng H, Iqbal J, Lenz G, Vose JM, Hans CP, Fu K, Smith LM, Li M, Liu Z, Gascoyne RD, Rosenwald A, Ott G, Rimsza LM, Campo E, Jaffe ES, Jaye DL, Staudt LM, Chan WC.
A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy.
Clin. Cancer Res. 15: 5494-502, 2009.
[Journal]
28)  Bidère N, Ngo VN, Lee J, Collins C, Zheng L, Wan F, Davis RE, Lenz G, Anderson DE, Arnoult D, Vazquez A, Sakai K, Zhang J, Meng Z, Veenstra TD, Staudt LM, Lenardo MJ.
Casein kinase 1alpha governs antigen-receptor-induced NF-kappaB activation and human lymphoma cell survival.
Nature. 458: 92-6, 2009.
[Journal]
29)  Dunleavy K, Pittaluga S, Czuczman MS, Dave SS, Wright G, Grant N, Shovlin M, Jaffe ES, Janik JE, Staudt LM, Wilson WH.
Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma.
Blood. 113: 6069-76, 2009.
[Journal]
30)  Hailfinger S, Lenz G, Ngo V, Posvitz-Fejfar A, Rebeaud F, Guzzardi M, Penas EM, Dierlamm J, Chan WC, Staudt LM, Thome M.
Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma.
Proc. Natl. Acad. Sci. U.S.A. 106: 19946-51, 2009.
[Journal]
31)  Shaffer AL, Emre NC, Romesser PB, Staudt LM.
IRF4: Immunity. Malignancy! Therapy?.
Clin. Cancer Res. 15: 2954-61, 2009.
[Journal]
32)  Lam LT, Davis RE, Ngo VN, Lenz G, Wright G, Xu W, Zhao H, Yu X, Dang L, Staudt LM.
Compensatory IKKalpha activation of classical NF-kappaB signaling during IKKbeta inhibition identified by an RNA interference sensitization screen.
Proc. Natl. Acad. Sci. U.S.A. 105: 20798-803, 2008.
[Journal]
33)  Lam LT, Wright G, Davis RE, Lenz G, Farinha P, Dang L, Chan JW, Rosenwald A, Gascoyne RD, Staudt LM.
Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma.
Blood. 111: 3701-13, 2008.
[Journal]
34)  Shaffer AL, Emre NC, Lamy L, Ngo VN, Wright G, Xiao W, Powell J, Dave S, Yu X, Zhao H, Zeng Y, Chen B, Epstein J, Staudt LM.
IRF4 addiction in multiple myeloma.
Nature. 454: 226-31, 2008.
[Journal]
35)  Lenz G, Wright GW, Emre NC, Kohlhammer H, Dave SS, Davis RE, Carty S, Lam LT, Shaffer AL, Xiao W, Powell J, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Connors JM, Campo E, Jaffe ES, Delabie J, Smeland EB, Rimsza LM, Fisher RI, Weisenburger DD, Chan WC, Staudt LM.
Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways.
Proc. Natl. Acad. Sci. U.S.A. 105: 13520-5, 2008.
[Journal]
36)  Lenz G, Davis RE, Ngo VN, Lam L, George TC, Wright GW, Dave SS, Zhao H, Xu W, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Fisher RI, Chan WC, Staudt LM.
Oncogenic CARD11 mutations in human diffuse large B cell lymphoma.
Science. 319: 1676-9, 2008.
[Journal]
37)  Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, Xu W, Tan B, Goldschmidt N, Iqbal J, Vose J, Bast M, Fu K, Weisenburger DD, Greiner TC, Armitage JO, Kyle A, May L, Gascoyne RD, Connors JM, Troen G, Holte H, Kvaloy S, Dierickx D, Verhoef G, Delabie J, Smeland EB, Jares P, Martinez A, Lopez-Guillermo A, Montserrat E, Campo E, Braziel RM, Miller TP, Rimsza LM, Cook JR, Pohlman B, Sweetenham J, Tubbs RR, Fisher RI, Hartmann E, Rosenwald A, Ott G, Muller-Hermelink HK, Wrench D, Lister TA, Jaffe ES, Wilson WH, Chan WC, Staudt LM.
Stromal gene signatures in large-B-cell lymphomas.
N. Engl. J. Med. 359: 2313-23, 2008.
[Journal]
38)  Davis RE, Zhang Y, Southall N, Staudt LM, Austin CP, Inglese J, Auld DS.
A cell-based assay for IkappaBalpha stabilization using a two-color dual luciferase-based sensor.
Assay Drug Dev. Technol. 5: 85-103, 2007.
[Journal]
39)  Staudt LM.
A closer look at follicular lymphoma.
N. Engl. J. Med. 356: 741-2, 2007.
[Journal]
40)  Lenz G, Nagel I, Siebert R, Roschke AV, Sanger W, Wright GW, Dave SS, Tan B, Zhao H, Rosenwald A, Muller-Hermelink HK, Gascoyne RD, Campo E, Jaffe ES, Smeland EB, Fisher RI, Kuehl WM, Chan WC, Staudt LM.
Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma.
J. Exp. Med. 204: 633-43, 2007.
[Journal]
41)  Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F, Lenz G, Hanamura I, Wright G, Xiao W, Dave S, Hurt EM, Tan B, Zhao H, Stephens O, Santra M, Williams DR, Dang L, Barlogie B, Shaughnessy JD, Kuehl WM, Staudt LM.
Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma.
Cancer Cell. 12: 115-30, 2007.
[Journal]
42)  Wiestner A, Tehrani M, Chiorazzi M, Wright G, Gibellini F, Nakayama K, Liu H, Rosenwald A, Muller-Hermelink HK, Ott G, Chan WC, Greiner TC, Weisenburger DD, Vose J, Armitage JO, Gascoyne RD, Connors JM, Campo E, Montserrat E, Bosch F, Smeland EB, Kvaloy S, Holte H, Delabie J, Fisher RI, Grogan TM, Miller TP, Wilson WH, Jaffe ES, Staudt LM.
Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival.
Blood. 109: 4599-606, 2007.
[Journal]
43)  Davies AJ, Rosenwald A, Wright G, Lee A, Last KW, Weisenburger DD, Chan WC, Delabie J, Braziel RM, Campo E, Gascoyne RD, Jaffe ES, Muller-Hermelink K, Ott G, Calaminici M, Norton AJ, Goff LK, Fitzgibbon J, Staudt LM, Andrew Lister T.
Transformation of follicular lymphoma to diffuse large B-cell lymphoma proceeds by distinct oncogenic mechanisms.
Br. J. Haematol. 136: 286-93, 2007.
[Journal]
44)  Shaffer AL, Wright G, Yang L, Powell J, Ngo V, Lamy L, Lam LT, Davis RE, Staudt LM.
A library of gene expression signatures to illuminate normal and pathological lymphoid biology.
Immunol. Rev. 210: 67-85, 2006.
[Journal]
45)  Sciammas R, Shaffer AL, Schatz JH, Zhao H, Staudt LM, Singh H.
Graded expression of interferon regulatory factor-4 coordinates isotype switching with plasma cell differentiation.
Immunity. 25: 225-36, 2006.
[Journal]
46)  Dave SS, Fu K, Wright GW, Lam LT, Kluin P, Boerma EJ, Greiner TC, Weisenburger DD, Rosenwald A, Ott G, Müller-Hermelink HK, Gascoyne RD, Delabie J, Rimsza LM, Braziel RM, Grogan TM, Campo E, Jaffe ES, Dave BJ, Sanger W, Bast M, Vose JM, Armitage JO, Connors JM, Smeland EB, Kvaloy S, Holte H, Fisher RI, Miller TP, Montserrat E, Wilson WH, Bahl M, Zhao H, Yang L, Powell J, Simon R, Chan WC, Staudt LM.
Molecular diagnosis of Burkitt's lymphoma.
N. Engl. J. Med. 354: 2431-42, 2006.
[Journal]
47)  Fu K, Weisenburger DD, Greiner TC, Dave S, Wright G, Rosenwald A, Chiorazzi M, Iqbal J, Gesk S, Siebert R, De Jong D, Jaffe ES, Wilson WH, Delabie J, Ott G, Dave BJ, Sanger WG, Smith LM, Rimsza L, Braziel RM, Müller-Hermelink HK, Campo E, Gascoyne RD, Staudt LM, Chan WC.
Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling.
Blood. 106: 4315-21, 2005.
[Journal]
48)  Bea S, Zettl A, Wright G, Salaverria I, Jehn P, Moreno V, Burek C, Ott G, Puig X, Yang L, Lopez-Guillermo A, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Gascoyne RD, Connors JM, Grogan TM, Braziel R, Fisher RI, Smeland EB, Kvaloy S, Holte H, Delabie J, Simon R, Powell J, Wilson WH, Jaffe ES, Montserrat E, Muller-Hermelink H, Staudt LM, Campo E, Rosenwald A, Lymphoma/Leukemia Molecular Profiling Project .
Diffuse Large B-Cell Lymphoma Subgroups Have Distinct Genetic Profiles that Influence Tumor Biology and Improve Gene Expression-Based Survival Prediction.
Blood. 106: 3183-90, 2005.
[Journal]
49)  Lam LT, Davis RE, Pierce J, Hepperle M, Xu Y, Hottelet M, Nong Y, Wen D, Adams J, Dang L, Staudt LM.
Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling.
Clin Cancer Res. 11: 28-40, 2005.
[Journal]
50)  Staudt LM, Dave S.
The biology of human lymphoid malignancies revealed by gene expression profiling.
Adv. Immunol. 87: 163-208, 2005.
[Journal]
51)  Rosenwald A, Chuang EY, Davis RE, Wiestner A, Alizadeh AA, Arthur DC, Mitchell JB, Marti GE, Fowler DH, Wilson WH, Staudt LM.
Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response.
Blood. 104: 1428-34, 2004.
[Journal]
52)  Hurt EM, Wiestner A, Rosenwald A, Shaffer AL, Campo E, Grogan T, Bergsagel PL, Kuehl WM, Staudt LM.
Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma.
Cancer Cell. 5: 191-9, 2004.
[Journal]
53)  Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, Fisher RI, Braziel RM, Rimsza LM, Grogan TM, Miller TP, LeBlanc M, Greiner TC, Weisenburger DD, Lynch JC, Vose J, Armitage JO, Smeland EB, Kvaloy S, Holte H, Delabie J, Connors JM, Lansdorp PM, Ouyang Q, Lister TA, Davies AJ, Norton AJ, Muller-Hermelink HK, Ott G, Campo E, Montserrat E, Wilson WH, Jaffe ES, Simon R, Yang L, Powell J, Zhao H, Goldschmidt N, Chiorazzi M, Staudt LM.
Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells.
N Engl J Med. 351: 2159-69, 2004.
[Journal]
54)  Shaffer AL, Shapiro-Shelef M, Iwakoshi NN, Lee AH, Qian SB, Zhao H, Yu X, Yang L, Tan BK, Rosenwald A, Hurt EM, Petroulakis E, Sonenberg N, Yewdell JW, Calame K, Glimcher LH, Staudt LM.
XBP1, downstream of Blimp-1, expands the secretory apparatus and other organelles, and increases protein synthesis in plasma cell differentiation.
Immunity. 21: 81-93, 2004.
[Journal]
55)  Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM.
A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma.
Proc Natl Acad Sci U S A. 100: 9991-6, 2003.
[Journal]
56)  Rosenwald A, Wright G, Leroy K, Yu X, Gaulard P, Gascoyne RD, Chan WC, Zhao T, Haioun C, Greiner TC, Weisenburger DD, Lynch JC, Vose J, Armitage JO, Smeland EB, Kvaloy S, Holte H, Delabie J, Campo E, Montserrat E, Lopez-Guillermo A, Ott G, Muller-Hermelink HK, Connors JM, Braziel R, Grogan TM, Fisher RI, Miller TP, LeBlanc M, Chiorazzi M, Zhao H, Yang L, Powell J, Wilson WH, Jaffe ES, Simon R, Klausner RD, Staudt LM.
Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to hodgkin lymphoma.
J Exp Med. 198: 851-62, 2003.
[Journal]
57)  Staudt LM.
Molecular diagnosis of the hematologic cancers.
N Engl J Med. 348: 1777-85, 2003.
[Journal]
58)  Rosenwald A, Wright G, Wiestner A, Chan WC, Connors JM, Campo E, Gascoyne RD, Grogan TM, Muller-Hermelink HK, Smeland EB, Chiorazzi M, Giltnane JM, Hurt EM, Zhao H, Averett L, Henrickson S, Yang L, Powell J, Wilson WH, Jaffe ES, Simon R, Klausner RD, Montserrat E, Bosch F, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Fisher RI, Miller TP, LeBlanc M, Ott G, Kvaloy S, Holte H, Delabie J, Staudt LM.
The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma.
Cancer Cell. 3: 185-97, 2003.
[Journal]
59)  Wiestner A, Rosenwald A, Barry TS, Wright G, Davis RE, Henrickson SE, Zhao H, Ibbotson RE, Orchard JA, Davis Z, Stetler-Stevenson M, Raffeld M, Arthur DC, Marti GE, Wilson WH, Hamblin TJ, Oscier DG, Staudt LM.
ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile.
Blood. 101: 4944-51, 2003.
[Journal]
60)  Shaffer AL, Lin KI, Kuo TC, Yu X, Hurt EM, Rosenwald A, Giltnane JM, Yang L, Zhao H, Calame K, Staudt LM.
Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program.
Immunity. 17: 51-62, 2002.
[Journal]
61)  Staudt LM.
Gene expression profiling of lymphoid malignancies.
Annu Rev Med. 53: 303-18, 2002.
[Journal]
62)  Shaffer AL, Rosenwald A, Staudt LM.
Lymphoid malignancies: the dark side of B-cell differentiation.
Nat Rev Immunol. 2: 920-32, 2002.
[Journal]
63)  Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, Wilson WH, Jaffe ES, Simon R, Klausner RD, Powell J, Duffey PL, Longo DL, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Montserrat E, López-Guillermo A, Grogan TM, Miller TP, LeBlanc M, Ott G, Kvaloy S, Delabie J, Holte H, Krajci P, Stokke T, Staudt LM, Lymphoma/Leukemia Molecular Profiling Project .
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.
N Engl J Med. 346: 1937-47, 2002.
[Journal]
64)  Davis RE, Brown KD, Siebenlist U, Staudt LM.
Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells.
J Exp Med. 194: 1861-74, 2001.
[Journal]
65)  Feske S, Giltnane J, Dolmetsch R, Staudt LM, Rao A.
Gene regulation mediated by calcium signals in T lymphocytes.
Nat Immunol. 2: 316-24, 2001.
[Journal]
66)  Lam LT, Pickeral OK, Peng AC, Rosenwald A, Hurt EM, Giltnane JM, Averett LM, Zhao H, Davis RE, Sathyamoorthy M, Wahl LM, Harris ED, Mikovits JA, Monks AP, Hollingshead MG, Sausville EA, Staudt LM.
Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol.
Genome Biol. 2: RESEARCH0041, 2001.
[Journal]
67)  Rosenwald A, Alizadeh AA, Widhopf G, Simon R, Davis RE, Yu X, Yang L, Pickeral OK, Rassenti LZ, Powell J, Botstein D, Byrd JC, Grever MR, Cheson BD, Chiorazzi N, Wilson WH, Kipps TJ, Brown PO, Staudt LM.
Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia.
J Exp Med. 194: 1639-47, 2001.
[Journal]
68)  Shaffer AL, Rosenwald A, Hurt EM, Giltnane JM, Lam LT, Pickeral OK, Staudt LM.
Signatures of the immune response.
Immunity. 15: 375-85, 2001.
[Journal]
69)  Shaffer AL, Yu X, He Y, Boldrick J, Chan EP, Staudt LM.
BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control.
Immunity. 13: 199-212, 2000.
[Journal]
70)  Staudt LM, Brown PO.
Genomic views of the immune system*.
Annu Rev Immunol. 18: 829-59, 2000.
[Journal]
71)  Lossos IS, Alizadeh AA, Eisen MB, Chan WC, Brown PO, Botstein D, Staudt LM, Levy R.
Ongoing immunoglobulin somatic mutation in germinal center B cell-like but not in activated B cell-like diffuse large cell lymphomas.
Proc Natl Acad Sci U S A. 97: 10209-13, 2000.
[Journal]
72)  Alizadeh A, Eisen M, Davis RE, Ma C, Sabet H, Tran T, Powell JI, Yang L, Marti GE, Moore DT, Hudson JR, Chan WC, Greiner T, Weisenburger D, Armitage JO, Lossos I, Levy R, Botstein D, Brown PO, Staudt LM.
The lymphochip: a specialized cDNA microarray for the genomic-scale analysis of gene expression in normal and malignant lymphocytes.
Cold Spring Harb Symp Quant Biol. 64: 71-8, 1999.
[Journal]
73)  Dent AL, Hu-Li J, Paul WE, Staudt LM.
T helper type 2 inflammatory disease in the absence of interleukin 4 and transcription factor STAT6.
Proc Natl Acad Sci U S A. 95: 13823-8, 1998.
[Journal]
74)  Dent AL, Shaffer AL, Yu X, Allman D, Staudt LM.
Control of inflammation, cytokine expression, and germinal center formation by BCL-6.
Science. 276: 589-92, 1997.
[Journal]
Click Here to View Collapsed Bibliography.

This page was last updated on 6/17/2014.